Welcome to our dedicated news page for Coya Therapeutics (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coya Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coya Therapeutics 's position in the market.
Rhea-AI Summary
Coya Therapeutics, Inc. (NASDAQ: COYA) expands COYA 302 pipeline into Alzheimer's Disease, leveraging synergistic mode of action with LD IL-2 and CTLA4-Ig. The partnership with Dr. Reddy's Laboratories in ALS is valued at up to $733 million. Ongoing double-blind trial for LD IL-2 in AD aims to support COYA 302 development. The company plans to file INDs for ALS and FTD in 2024, with additional clinical updates and expansion of combination therapies beyond COYA 302.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
-
Rhea-AI Summary
Coya Therapeutics, Inc. (NASDAQ: COYA) expands patent estate with a license from University of Nebraska Medical Center for multiple low dose interleukin-2 (ld IL-2) combinations, including ld IL-2 + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF). The combination results in a 4-6 fold synergistic increase in Tregs, enhancing Treg function and lowering inflammation. UNeMed will receive payments and royalties. The license strengthens Coya's multi-pathway approach in developing immunomodulatory drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
-
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces that Dr. Stanley Appel will present at the Society of Neuroimmune Pharmacology Conference on March 11, 2024. The presentation will discuss the potential of combination immunotherapy in treating neuroinflammatory conditions like ALS, FTD, and PD. Dr. Appel will highlight the prevalence of systemic immune and inflammatory factors in ALS and the potential of COYA 302 therapy. The presentation aims to share findings on targeting multiple immunomodulatory pathways to overcome the redundancy of the immune system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) announces participation in Chardan Capital Market’s biotechnology Leadership Call Series. The company's CEO, CBO, and CMO will discuss their pioneering drug development efforts in Treg-enhancing therapies for neurodegenerative diseases, specifically COYA 302. Interested investors can request attendance to the live virtual event by emailing Chardan. A replay of the session will be available on Coya’s website following the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
-
Rhea-AI Summary
Coya Therapeutics, Inc. announces the expansion of its pipeline to include frontotemporal dementia and Parkinson's disease in addition to ALS. The company has developed COYA 302, a proprietary biologic combination immunotherapy targeting multiple pathways to address the proinflammatory environment underlying these diseases. The company has also provided strong and productive milestone and catalyst updates for 2024, with cash runway guidance extending into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
-
Rhea-AI Summary
DISCO Pharmaceuticals, a specialist biotech company, has emerged from stealth with a transformative surfaceome discovery technology to identify new targets and develop first-in-class drugs for cancer treatment. The company has successfully raised seed financing of EUR 20 million and is backed by a world-leading investor syndicate. DISCO has completed the first-ever map of the surfaceome of Small Cell Lung Cancer and is developing proprietary antibody-based treatments for it. The company is also working on Microsatellite-Stable Colorectal Cancer and has a pipeline of further undisclosed programs. The experienced team, led by CEO Roman Thomas, includes leading biopharma executives Dieter Weinand and Carsten Reinhardt. The company's surfaceome mapping platform has the potential to transform oncology treatment options and improve outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.27%
Tags
Rhea-AI Summary
Coya Therapeutics, Inc. (COYA) has successfully obtained constructive feedback and reached alignment with the FDA on key areas involved in the development of COYA 302, a dual-mechanism investigational biologic combination therapy for the treatment of ALS. This significant step paves the way for the submission of the IND application to the FDA in the second quarter of 2024 and the initiation of a well-controlled, double-blind clinical trial of COYA 302 in ALS patients. The company has secured a cash runway into 2026 through recent out-licensing and private placement transactions, positioning it to deliver value to patients and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
-
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) has appointed Secretary Wilbur Ross, former Chairman and Chief Strategy Officer of WL Ross & Co., to its board of directors. The clinical-stage biotechnology company aims to leverage Secretary Ross's extensive experience in business and investment to guide strategic partnering activities, capital markets initiatives, and drug development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.66%
Tags
-
Rhea-AI Summary
Coya Therapeutics, Inc. (NASDAQ: COYA) has announced a transformative licensing transaction with Dr. Reddy's Laboratories (DRL) providing up to $733 MM in non-dilutive upfront payments and potential sales and regulatory milestones. The company also successfully closed a private placement financing of $26.5 MM, anticipating a cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) closed a private placement offering of 4,370,382 shares of common stock, raising $26.5 million. Net proceeds are expected to be approximately $24.1 million, intended for general corporate purposes, working capital, and to support preclinical, clinical, and regulatory activities. The financing is anticipated to fund operations into 2026, with participation from former U.S. Secretary of Commerce Wilbur Ross and other existing institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
Coya Therapeutics, Inc.
Nasdaq:COYA
COYA Rankings
COYA Stock Data
126.60M
9.97M
7.95%
17.57%
1.31%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
HOUSTON